Study on the clinical efficacy of regorafenib (Baivange) in patients with liver cancer

Regorafenib is an oral multi-target tyrosine kinase inhibitor that can inhibit various signaling pathways such as VEGFR, PDGFR, KIT, RET and other signaling pathways, thereby exerting anti-tumor effects. It inhibits liver cancer cells by blocking signaling pathways related to angiogenesis, tumor growth and metastasis. Regorafenib has been widely studied for use in patients with advanced hepatocellular carcinoma (HCC), especially in the second-line treatment after sorafenib (Sorafenib) resistance or treatment progression, showing significant efficacy.

Clinical studies have shown that the efficacy of regorafenib in patients with liver cancer is mainly reflected in prolonging overall survival (OS) and progression-free survival (PFS). According to the REGORAFE study and other clinical trial data, for patients with advanced liver cancer who have previously received sorafenib treatment and whose disease has progressed, second-line treatment with regorafenib can extend the median overall survival to approximately 10.6 months. The median overall survival of the control group was approximately 7.8 months; the median progression-free survival was approximately 3.1 months, which was significantly longer than the 1.5 months of the control group. This shows that regorafenib has clear advantages in delaying disease progression and improving survival rates.

In terms of objective efficacy, the objective response rate (ORR) of regorafenib is approximately7%~10% , the disease control rate (DCR) can reach 65%~70%, showing a relatively high disease stabilization ability. Most patients can observe tumor shrinkage or stable disease within the first few months of treatment, and some patients can maintain long-term control. In addition, regorafenib also has certain positive effects in improving the quality of life and delaying the worsening of symptoms, such as alleviating ascites, worsening liver function, and decreased physical strength, thereby improving patients' daily living abilities.

In terms of side effects, the safety and tolerability of regorafenib are generally controllable, but attention should still be paid to common adverse reactions, including hypertension, hand-foot skin reaction, fatigue, diarrhea, and increased liver function indicators. Clinically, it is recommended to regularly monitor blood pressure, liver function and hematological indicators during medication so that abnormalities can be detected promptly and corresponding intervention measures can be taken, such as dose adjustment or symptomatic treatment. At the same time, for patients with hepatic insufficiency or underlying diseases, individualized dosage adjustments should be made under the guidance of a doctor to ensure the safety and efficacy of treatment to the greatest extent.

Taken together, regorafenib, as a second-line treatment for advanced hepatocellular carcinoma, has shown good efficacy in prolonging the overall survival of patients, delaying disease progression, and maintaining disease control. Its application in patients who have failed previous sorafenib treatment provides an important treatment option and brings new hope to patients with advanced liver cancer. At the same time, through standardized monitoring and individualized management, regorafenib can achieve ideal therapeutic effects while ensuring safety.

Reference link:https://www.drugs.com